Skip to main content
. 2022 Dec 20;11(1):2. doi: 10.3390/vaccines11010002

Figure 4.

Figure 4

cVLP-PCSK9 vaccines induce antigen-specific antibody titers in mice. Plasma samples were obtained from male BALB/c mice (n = 8 per group) two weeks after prime (1st bleed), boost (2nd bleed) and second boost (3rd bleed), respectively. (A). Total IgG anti-PCSK9 dilution curve (3rd bleed) detected in mice vaccinated with cVLP-PCSK9(210–226) (pink), cVLP-PCSK9(156–227) (blue), cVLP-PCSK9(FL) (green), soluble PCSK9-SpyT (orange) or unconjugated SpyC-cVLP (black). Variance is shown as geometric mean ± geometric SD (B). Total IgG anti-PCSK9 titers are depicted as AUC with mean ± SD from 1st, 2nd and 3rd bleeds. (C–F). anti-PCSK9 IgG subclass (C). IgG1, (D). IgG2a, (E). IgG2b, (F). IgG3 depicted as AUC titer with mean ± SD detected in plasma from mice vaccinated with cVLP-PCSK9(210–226), cVLP-PCSK9(156–227), cVLP-PCSK9(FL) and soluble FL PCSK9-SpyT. Statistical analysis was performed on log-transformed AUC values using one-way ANOVA, Tukey’s multiple comparisons test (adjusted p-value < 0.05 was accepted as significant, ns > 0.05, * < 0.05, **** < 0.0001).